CSTL vs MYGN
CSTL: Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin cancers, Barrett's esophagus, and atopic dermatitis. MYGN: Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes.
Side-by-side fundamentals
| Metric | CSTL | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.81 | $5.66 | |
| Market cap as of 2026-07-23 | $749M | $547M | |
| PEG as of 2026-07-23 | -0.49 | -0.00 | CSTL lower |
| Net margin as of 2026-07-23 | -3.8% | -48.2% | CSTL higher |
| Gross margin as of 2026-07-23 | +77.9% | +70.0% | CSTL higher |
| Operating margin as of 2026-07-23 | -9.8% | -46.9% | CSTL higher |
| ROE as of 2026-07-23 | -2.8% | -109.1% | CSTL higher |
| ROA as of 2026-07-23 | -2.3% | -57.4% | CSTL higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.36 | CSTL lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.1% | -0.3% | MYGN higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | +6.7% | CSTL higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.02 | 1.62 | |
| 1-year return as of 2026-07-22 close | +52.0% | +23.3% | CSTL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.